{"filing":{"accession_number":"0001104659-26-075775","cik":"0001390478","ticker":"SLS","company_name":"SELLAS Life Sciences Group, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618311d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/tm2618311d1_8k.htm"},"events":[{"id":11903,"run_id":10475,"accession_number":"0001104659-26-075775","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 16, 2026, covering five proposals: director elections (Proposal 1), auditor ratification (Proposal 2), equity plan amendment (Proposal 3), executive compensation advisory vote (Proposal 4), and meeting adjournment (Proposal 5). The filing presents voting tallies for each proposal, which is the core content of Item 5.07 disclosures. Director elections and equity plan amendments are material to investors' assessment of governance and capital structure.","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8615,"accession_number":"0001104659-26-075775","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 16, 2026, covering five proposals: director elections (Proposal 1), auditor ratification (Proposal 2), equity plan amendment (Proposal 3), executive compensation advisory vote (Proposal 4), and meeting adjournment (Proposal 5). The filing presents voting tallies for each proposal, which is the core content of Item 5.07 disclosures. Director elections and equity plan amendments are material to investors' assessment of governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:33:35.558436+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8615,"accession_number":"0001104659-26-075775","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 16, 2026, covering five proposals: director elections (Proposal 1), auditor ratification (Proposal 2), equity plan amendment (Proposal 3), executive compensation advisory vote (Proposal 4), and meeting adjournment (Proposal 5). The filing presents voting tallies for each proposal, which is the core content of Item 5.07 disclosures. Director elections and equity plan amendments are material to investors' assessment of governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:33:35.558436+00:00","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-06-18"}]}